Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (9)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

2022

  1. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

    Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67

  2. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

    Blood Advances, Vol. 6, Núm. 24, pp. 6219-6227

2021

  1. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2019

  1. On the cost-utility of methylene blue-photoinactivated plasma versus quarantine plasma in Spain

    Blood Transfusion

2015

  1. Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group

    Medicina Clinica, Vol. 144, Núm. 7, pp. 331.e1-331.e13

2009

  1. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment

    Annals of Hematology, Vol. 88, Núm. 10, pp. 973-978

2008

  1. ADAMTS-13 activity and von Willebrand factor levels in methylene blue photo-inactivated plasma processed by either the Springe method or an 'in house' system

    Vox Sanguinis, Vol. 95, Núm. 2, pp. 101-105

  2. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: A multicentric, prospective cohort study

    British Journal of Haematology, Vol. 143, Núm. 1, pp. 39-45